Ioforminol

Drug Profile

Ioforminol

Alternative Names: AN 113111; GE 145

Latest Information Update: 25 May 2016

Price : $50

At a glance

  • Originator GE Healthcare
  • Developer Daiichi Sankyo Company; GE Healthcare
  • Class Amides; Aza compounds; Contrast media; Diagnostic agents; Imaging agents; Iodobenzenes; Small molecules
  • Mechanism of Action Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Vascular disorders

Most Recent Events

  • 01 Dec 2012 GE Healthcare completes a phase II trial in Vascular disorders (diagnosis, in the elderly) in USA (NCT01252810)
  • 01 Aug 2012 GE Healthcare completes a phase I/II trial in Vascular disorders (healthy volunteers) in USA (NCT01672996)
  • 07 Jul 2012 GE Healthcare initiates enrolment in a phase I/II trial in Diagnostic imaging (in healthy volunteers) in USA (NCT01672996)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top